Are pre-terms born timely and right immunized? Results of an Italian cohort study

Figures & data

Table 1. Demographical characteristics of children enrolled (n = 159), per gender.

Characteristics	Males (n = 100)	Females (n = 59)	Total (n = 159)	test	p
Birth weight, grams	1,867.3±577.4 (720,0–3,280.0)	1,732.3±541.1 (650.0–2,920.0)	1,817.2±566.2 (650.0–3,280.0)	t = 1.5	0.147
Gestational age at birth, weeks	32.9±3.3 (21.3–40.7)	32.7±3.0 (25.1–39.1)	32.8±3.2 (21.3–40.7)	t = 0.4	0.714
Chronological age at NICU discharge, days	33.3±36.3 (3.0–165.0)	36.0±41.0 (2.0–194.0)	34.8±39.3 (2.0–194.0)	z = 0.2	0.814

Table 2. Immunization coverage of preterm enrolled babies and full term infants (Apulia birth cohorts 2012–2014).

Vaccine	n. enrolled subjects*	n. of vaccinated subjects	% vaccinated (95% CI)	Apulian Vaccination Coverage 2012–14 birth cohorts	z	p
DTaP-IPV-HBV-Hib 1 dose	159	156	98.1 (94.6–99.6)	93.2	2.5	0.014
DTaP-IPV-HBV-Hib 2 doses	159	145	91.2 (85.7–95.1)	91.6	0.2	0.856
DTaP-IPV-HBV-Hib 3 doses	158	138	87.3 (81.1–92.1)	88.0	0.3	0.789
PCV 1 dose	159	157	98.7 (95.5–99.8)	92.5	3.0	0.003
PCV 2 doses	159	144	90.6 (84.9–94.6)	90.8	0.1	0.931
PCV 3 doses	158	136	86.1 (79.7–91.1)	86.8	0.3	0.795
MMR	157	120	76.4 (69.0–82.8)	78.7	0.7	0.482
Men C	157	135	86.0 (79.6–91.0)	84.4	0.6	0.581
Varicella	157	127	80.9 (73.9–86.7)	82.3	0.5	0.646

*for some subjects, complete immunization information were not available

Table 3. Average age at vaccine administration in preterm borns

Vaccine	Mean±ds age of immunization (days)	Recommended age (days)	t	p
DTaP-IPV-HBV-Hib 1 dose	118.0 ± 85.1	61.0	8.4	0.000
DTaP-IPV-HBV-Hib 1 dose after NICU discharge	124.0 ± 93.1	61.0	8.1	0.000
DTaP-IPV-HBV-Hib 1 dose during hospitalization	96.1 ± 17.7	61.0	7.4	0.000
DTaP-IPV-HBV-Hib 2 doses	195.0 ± 94.0	121.0	9.5	0.000
DTaP-IPV-HBV-Hib 3 doses	426.0 ± 136.9	336.0	7.7	0.000
PCV 1 dose	123.0 ± 92.1	61.0	8.4	0.000
PCV 2 doses	196.0 ± 94.3	121.0	9.5	0.000
PCV 3 doses	423.0 ± 131.7	336.0	7.7	0.000
MMR	617.0 ± 202.8	426.0	10.3	0.000
Men C	550.0 ± 239.7	366.0	8.9	0.000
Varicella	540.0 ± 207.0	366.0	9.5	0.000

Table 4. Time intervals between 1st / 2nd dose and 3rd / 2nd dose of hexavalent and anti-pneumococcal vaccine and the gold standard intervals.

Variables	Mean ± SD (days)	Gold standard (days)	t	p
Time between hexavalent 2nd dose – hexavalent 1st dose	84.4 ± 70.1	60.0	4.2	0.000
Time between hexavalent 3rd dose – hexavalent 2nd dose	236.0 ± 90.3	215.0	2.7	0.007
Time between anti-pneumococcal 2nd dose – anti-pneumococcal 1st dose	84.0 ± 69.4	60.0	4.1	0.000
Time between anti-pneumococcal 3rd dose – anti-pneumococcal 2nd dose	231.9 ± 85.4	215.0	2.3	0.023